Santhera’s Raxone gets early patient access under U.K. scheme

Santhera Pharmaceuticals Holding AG (SIX: SANN) gained CHF8.85 (15%) to CHF67.20 after it said a positive scientific opinion from U.K. regulators would give patients with Duchenne muscular dystrophy (DMD) access to the company's Raxone idebenone under the country's Early Access to Medicines Scheme (EAMS).

Santhera will provide Raxone free of charge to DMD patients with declining respiratory function who have been previously treated with or intolerant to glucocorticoids...